SCHEMBL30378346

SCHEMBL30378346

C[C@@H]1CN(c2ccccn2)C[C@H](C)O1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.50
KDM4E B2RXH2 3/20 0.50
KMT2A Q03164 2/20 0.50
GAA P10253 1/20 0.50
HPGD P15428 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
GRIN2B Q13224 5/20 0.48
PLD1 Q13393 1/20 0.47
GRM1 Q13255 3/20 0.46
TSHR P16473 1/20 0.44
MEN1 O00255 1/20 0.44
HSD11B1 P28845 1/20 0.44
MAPT P10636 1/20 0.44
GRIN2D O15399 1/20 0.44
GRIN3B O60391 1/20 0.44
GRIN1 Q05586 1/20 0.44
GRIN2A Q12879 1/20 0.44
GRIN2C Q14957 1/20 0.44
GRIN3A Q8TCU5 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23875355 1.00 ALDH1A1 (0.50) ALDH1A1KDM4EKMT2AGAAHPGD
SCHEMBL29505307 1.00 ALDH1A1 (0.50) ALDH1A1KDM4EKMT2AGAAHPGD
Formamide SCHEMBL28688411 0.91 HSD11B1 (0.44) ALDH1A1KDM4EKMT2AGAAHPGD
SCHEMBL5341226 0.89 DPP4 (0.43) ALDH1A1KDM4EKMT2AGAAHPGD
SCHEMBL26972607 0.86 KDM4E (0.43) ALDH1A1KDM4EKMT2AGAAGRIN2B
SCHEMBL23875353 0.83 PLD1 (0.52) ALDH1A1KDM4EHPGDGRIN2BPLD1
SCHEMBL23860310 0.80 CHI3L1 (0.46) ALDH1A1KDM4EHPGDGRIN2BPLD1
SCHEMBL23875357 0.80 CHI3L1 (0.46) ALDH1A1KDM4EHPGDGRIN2BPLD1
SCHEMBL29991351 0.80 GRIN2B (0.49) ALDH1A1KDM4EGRIN2BPLD1GRM1
SCHEMBL22837869 0.79 HSD11B1 (0.50) ALDH1A1KDM4EGRIN2BPLD1GRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4739683-A1 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS Janssen Pharmaceutica NV (BE) 2026-05-13 EP claimed
WO-2025008059-A1 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS JANSSEN PHARMACEUTICA NV (BE) 2025-01-09 WO claimed
US-20230129003-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-04-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230129003-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB ALDH1A1 2571/4885KDM4E 1848/4885KMT2A 792/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.